BRR OpCo’s Trinity Biotech TRIB Stock Holding History

BRR OpCo’s Portfolio TRIB Stock Details TRIB Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2017 Q4	–	Sell	-2,827	Closed	-$79K	–	109
2017 Q3	$79K	Buy	+2,827	New	+$78.8K	0.02%	102

Other funds holding TRIB

PIM

Paradice Investment Management Denver, Colorado $532M AUM 29.6% 1-Year Est. Return

Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return

Heartland Advisors Milwaukee, Wisconsin $1.96B AUM 28.26% 1-Year Est. Return

Russell Investments Group London, United Kingdom $93.1B AUM 28.26% 1-Year Est. Return

LAM

Lapides Asset Management Greenwich, Connecticut $153M AUM 9.03% 1-Year Est. Return

Boston Partners Boston, Massachusetts $95.5B AUM 28.4% 1-Year Est. Return

FWSM

First Wilshire Securities Management Pasadena, California $444M AUM 42.88% 1-Year Est. Return

Senvest Management New York $3.01B AUM 35.7% 1-Year Est. Return

22NW LP Seattle, Washington $146M AUM 29.83% 1-Year Est. Return

SCM

Stonehill Capital Management New York $197M AUM 96.45% 1-Year Est. Return

BRR OpCo's TRIB Position: Q4 2017 in Review

BRR OpCo sold out of Trinity Biotech (TRIB) in Q4 2017, closing a stake of 2,827 shares — an estimated $79K sold.

BRR OpCo first reported a position in TRIB in Q3 2017 and held it in 1 quarter. The position peaked at $79K in Q3 2017. 48 funds tracked by Wall St. Rank hold TRIB as of Q4 2017.

BRR OpCo reported no remaining Trinity Biotech position as of Q4 2017 after selling out during the quarter.
BRR OpCo sold 2,827 Trinity Biotech shares in Q4 2017, an estimated $79K.
BRR OpCo first reported a position in Trinity Biotech in Q3 2017 and held it in 1 quarter.
BRR OpCo's Trinity Biotech position peaked at $79K in Q3 2017.
48 funds tracked by Wall St. Rank held Trinity Biotech as of Q4 2017.

Based on BRR OpCo's 13F filing for Q4 2017, filed 13 Feb 2018.